Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.

Neuroblastoma, the most common solid tumor of infancy derived from the sympathetic nervous system, continues to present a formidable clinical challenge. Sterically stabilized immunoliposomes (SIL) have been shown to enhance the selective localization of entrapped drugs to solid tumors, with improvements in therapeutic indices. We showed that SIL loaded with doxorubicin (DXR) and targeted to the disialoganglioside receptor GD(2) [aGD(2)-SIL(DXR)] led to a selective inhibition of the metastatic growth of experimental models of human neuroblastoma. By coupling NGR peptides that target the angiogenic endothelial cell marker aminopeptidase N to the surface of DXR-loaded liposomes [NGR-SL(DXR)], we obtained tumor regression, pronounced destruction of the tumor vasculature, and prolonged survival of orthotopic neuroblastoma xenografts. Here, we showed good liposome stability, long circulation times, and enhanced time-dependent tumor accumulation of both the carrier and the drug. Antivascular effects against animal models of lung and ovarian cancer were shown for formulations of NGR-SL(DXR). In the chick embryo chorioallantoic assay, NGR-SL(DXR) substantially reduced the angiogenic potential of various neuroblastoma xenografts, with synergistic inhibition observed for the combination of NGR-SL(DXR) with aGD(2)-SIL(DXR). A significant improvement in antitumor effects was seen in neuroblastoma-bearing animal models when treated with the combined formulations compared with control mice or mice treated with either tumor- or vascular-targeted liposomal formulations, administered separately. The combined treatment resulted in a dramatic inhibition of tumor endothelial cell density. Long-term survivors were obtained only in animals treated with the combined tumor- and vascular-targeted formulations, confirming the pivotal role of combination therapies in treating aggressive metastatic neuroblastoma.

[1]  H. Sather,et al.  Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. , 1991, The New England journal of medicine.

[2]  G. Colombo,et al.  Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif. , 2006, Molecular immunology.

[3]  D. Ribatti,et al.  Human neuroblastoma cells produce extracellular matrix‐degrading enzymes, induce endothelial cell proliferation and are angiogenic in vivo , 1998, International journal of cancer.

[4]  H. Kalthoff,et al.  An improved orthotopic xenotransplant procedure for human lung cancer in SCID bg mice. , 2000, The Annals of thoracic surgery.

[5]  D. Cheresh,et al.  Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. , 1984, Cancer research.

[6]  Theresa M. Allen,et al.  Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer Tumors , 2005, Clinical Cancer Research.

[7]  Y. Barenholz,et al.  Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. , 1994, Cancer research.

[8]  J Folkman,et al.  Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.

[9]  Kristian Pietras,et al.  A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Fulvio Magni,et al.  Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13) , 2000, Nature Biotechnology.

[11]  W. Fiers,et al.  Tumor necrosis factor‐α augmented tumor response in B16BL6 melanoma‐bearing mice treated with stealth liposomal doxorubicin (Doxil®) correlates with altered Doxil® pharmacokinetics , 2004, International journal of cancer.

[12]  Luigi Naldini,et al.  Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. , 2005, Cancer cell.

[13]  T. Allen,et al.  Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs. , 2004, Journal of the National Cancer Institute.

[14]  E. Moase,et al.  Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. , 1995, Biochimica et biophysica acta.

[15]  E. Ruoslahti,et al.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.

[16]  F. Pastorino,et al.  Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse. , 2003, Cancer letters.

[17]  P. Wesseling,et al.  AMINOPEPTIDASE A IS A CONSTITUENT OF ACTIVATED PERICYTES IN ANGIOGENESIS , 1996, The Journal of pathology.

[18]  J. Grandis,et al.  Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  D. Ribatti,et al.  Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. , 2003, Cancer research.

[20]  S. Johnson,et al.  Anthracyclines in haematology: preclinical studies, toxicity and delivery systems. , 1997, Blood reviews.

[21]  T. Allen.  Ligand-targeted therapeutics in anticancer therapy , 2002, Nature Reviews Cancer.

[22]  G. Giaccone,et al.  Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Erkki Ruoslahti,et al.  Anti-cancer activity of targeted pro-apoptotic peptides , 1999, Nature Medicine.

[24]  L. Ellis,et al.  The implications of angiogenesis for the biology and therapy of cancer metastasis , 1994, Cell.

[25]  R Pasqualini,et al.  Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. , 2000, Cancer research.

[26]  A. Rojiani,et al.  Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy , 2002, International journal of cancer.

[27]  D. Stuart,et al.  Targeted delivery of antisense oligonucleotides in cancer. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[28]  M. Bednarski,et al.  Tumor Regression by Targeted Gene Delivery to the Neovasculature , 2002, Science.

[29]  E. Moase,et al.  Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. , 2003, Cancer research.

[30]  H. Shimada,et al.  Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. , 1998, Cancer research.

[31]  Chiara Brignole,et al.  Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. , 2006, Journal of the National Cancer Institute.

[32]  L. Ellis,et al.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[34]  W. Wilson,et al.  Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) , 2002, Cancer Chemotherapy and Pharmacology.

[35]  T. Allen,et al.  In vitro and in vivo antitumor activity of liposomal fenretinide targeted to human neuroblastoma , 2003, International journal of cancer.

[36]  K K Matthay,et al.  Molecular biology of neuroblastoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Pieter Wesseling,et al.  Aminopeptidase A is a functional target in angiogenic blood vessels. , 2004, Cancer cell.

[38]  T. Allen,et al.  In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. , 2001, Biochimica et biophysica acta.

[39]  L. Mayer,et al.  Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  Rong Zhou,et al.  Antivascular and antitumor activities of liposome-associated drugs. , 2004, Anticancer research.

[41]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[42]  B. Calabretta,et al.  Delivery of c-myb Antisense Oligodeoxynucleotides to Human Neuroblastoma Cells Via Disialoganglioside GD2-Targeted Immunoliposomes: Antitumor Effects. , 2000, Journal of the National Cancer Institute.

[43]  T. Allen,et al.  Improved Outcome When B-Cell Lymphoma Is Treated with Combinations of Immunoliposomal Anticancer Drugs Targeted to Both the CD19 and CD20 Epitopes , 2004, Clinical Cancer Research.

[44]  Theresa M Allen,et al.  Anti-CD19-Targeted Liposomal Doxorubicin Improves the Therapeutic Efficacy in Murine B-Cell Lymphoma and Ameliorates the Toxicity of Liposomes with Varying Drug Release Rates , 2005, Clinical Cancer Research.

[45]  A Vacca,et al.  New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorioallantoic membrane assay. , 1997, Journal of vascular research.

[46]  T. Allen,et al.  GD2‐mediated melanoma cell targeting and cytotoxicity of liposome‐entrapped fenretinide , 1999, International journal of cancer.

[47]  S. Gillies,et al.  Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. , 1997, Journal of the National Cancer Institute.

[48]  S. Cannistra.  Cancer of the ovary. , 1993, The New England journal of medicine.

[49]  A. Rademaker,et al.  Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  V. Pistoia,et al.  Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. , 1995, Cancer research.